Cost-Effectiveness of Left Ventricular Assist Device for Transplant-Ineligible Patients.

ABSTRACT:

Importance

Singapore is considering subsidizing left ventricular assist devices (LVADs) for end-stage heart failure (ESHF) and uses cost-effectiveness evidence to inform the determination. Yet, no economic evaluation has thus far been conducted.

Objective

To estimate the lifetime cost-effectiveness of LVAD compared with optimal medical management for transplant-ineligible patients.

Design, setting, and participants

This economic evaluation used a Markov model to simulate survival, stroke incidence, other adverse events, and heart failure hospitalizations for a cohort of adult patients in Singapore with transplant-ineligible ESHF, most of whom were inotrope dependent. Latest LVAD mortality data from a randomized clinical trial were age-adjusted, and an indirect compari

SUBMITTER: Schaffer EM 

PROVIDER: S-EPMC12008763 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature